https://doi.org/10.31288/oftalmolzh201851519

Received: 30 May  2018; Published on-line: 26 October 2018

Efficacy of bioflavonoid quercetin in treatment of herpetic keratitis patients with dry eye syndrome

S. Ya. Rafalyuk1; T.B. Gaydamaka2, Dr. Sc. (Med.)

1 Danylo Halytsky Lviv National Medical University; 

Lviv (Ukraine)

2 Filatov Institute of Eye Diseases and Tissue Therapy, NAMS of Ukraine"

Odesa (Ukraine)

E-mail:  sofiyaeye@ukr.net

TO CITE THIS ARTICLE: Rafalyuk SYa, Gaydamaka TB. Efficacy of bioflavonoid quercetin in treatment of herpetic keratitis patients with dry eye syndrome. J.ophthalmol.(Ukraine).2018;5:15-19. https://doi.org/10.31288/oftalmolzh201851519

Introduction. Dry eye syndrome has drown a  special attention of ophthalmologists not only because of its prevalence but also due to the increased frequency among patients with inflammatory processes in the cornea and conjunctiva.

Purpose. To study the effect of bioflavonoid quercetin on the course of the inflammatory process in patients with herpetic keratitis (HK) and dry eye syndrome (DES).  

Material and Methods. Clinical study involved 40 patients (40 eyes) with HK (superficial keratitis) and DES; in addition, we followed up 17 patients (17 eyes) with HK-only. All patients involved in the clinical study were divided into two groups: Study Group, HK and DES patients receiving bioflavonoid quercetin, containing in Lipoflavon drug, in addition to traditional treatment, 15 patients; Control Group, HK and DES patients receiving only traditional treatment, 25 patients. 

Results. Clinical study findings showed that the inclusion of bioflavonoid quercetin (Lipoflavon) in the complex treatment of HK patients with DES significantly decreased the intensity of clinical signs and made it possible to decrease the treatment duration. Corneal dendritic ulceration epithelization was observed significantly earlier in patients with HK and SED receiving Lipoflafon as compared to controls, at Day (4.7±0.4) vs. Day (6.8±0.6), respectively; no corneal infiltration was observed at Days (5.5±0.5) and (7.8±0.7) in Study and Control groups, respectively. Schirmer test II values were (10.47±0.83) mm/5 min and (7.36±0.28) mm/5 min in Study and Control groups, respectively. Tear break-up time equaled (6.13±0.32) and (5.24±0.19) s, in Study and Control groups, respectively.

Conclusions. Inclusion of bioflavonoid quercetin in the complex treatment of patients with herpetic keratitis and dry eye syndrome significantly increases the therapy efficacy, which is evidenced by accelerated corneal epithelization and infiltrate dispersion and significantly improved qualitative and quantitative characteristics of tear production.

Keywords: herpetic keratitis, dry eye syndrome, Lipoflavon

 

References

1.Anina EI. [The prevalence of the cornea diseases among the population of Ukraine. Abstracts of II Black Sea International scientific conference ophthalmologists]. Odessa, 2004:14. Ukrainian

2.Brzheskij VV. [Diseases of the lacrimal apparatus: a manual for practicing doctors. 2nd ed. St. Petersburg].: Izdatelstvo N.-L .; 2009.106 p. Russian

3.Drozhzhina GI. [Modern methods of treatment of the dry eye syndrome]. Ophthal Zh. 2013; 5: 89-95. Ukrainian

4.Drozhzhina GI. [Viral diseases of the cornea and conjunctiva]. Zdorovya Ukrainy. 2002;5:35-36. Ukrainian

5.Zhaboedov DG, Kireev VV. [Dry eye syndrome: clinical picture, diagnosis and treatment. Guidelines for medical students and practitioners]. Kyiv, 2006. 24 p. Ukrainian

6.Nasledov A. [SPSS computer analysis of data analysis in psychology and social sciences].Spb.: Piter; 2005.416 p. Russian

7.Gaydamaka TB, Rafalyuk SY. [Effect of Lipoflavone on the activity of oxidation-reduction enzymes in tear fluid in keratitis in patients with dry eye syndrome]. Oftalmologiia. 2016.2:54-7. Ukrainian

8.Rafalyuk SY. [The possibility of metabolic correction of pathological disorders of the cornea in induced keratitis in animals with dry eye syndrome]. Oftalmologiia. 2015.2:211-20. Ukrainian

9.Skripnik RL, Skripnichenko RL. [New in the treatment of dry eye syndrome]. Ukr. Med. Chasopys.2011.1 (81): 79-80. Ukrainian

10.Somov EE. [Tear dysfunction syndrome: anatomic and physiological basis, diagnosis, clinical picture and treatment]. St. Petersburg: Chelovek; 2011.160 p. Russian

11.Somov EE. [Etiopathogenetic basis of the "dry eye" syndrome and principles of approach to its treatment. In: Materials of the jubilee scientific conference dedicated to the 75th anniversary of the foundation of the first in Russia Department of Children's Ophthalmology "Nevskie Horizonty-2010"].St. Petersburg, 2010.Oct.2:482-487. Russian

12.Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001 Mar;45 Suppl 2:S211-20.
Crossref

13.Begley CG, Chalmers RL, Abetz L, Venkataraman K, Mertzanis P, Caffery BA, Snyder C, Edrington T, Nelson D, Simpson T. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4753-61.
Crossref

PMid:14578396

14.Bourcier T, Acosta MC, Borderie V, Borrás F, Gallar J, Bury T, Laroche L, Belmonte C. Decreased corneal sensitivity in patients with dry eye. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2341-5.
Crossref

PMid:15980220 

15.Brewitt H, Sistani F. Dry eye disease: the scale of the problem. Surv Ophthalmol. 2001 Mar;45 Suppl 2:S199-202.
Crossref

16.Javadi MA, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res. 2011 Jul;6(3):192-8.

PMid:22454735 PMCid:PMC3306104

17.Wilson SE, Netto M, Ambrósio R Jr. Corneal cells: chatty in development, homeostasis, wound healing, and disease. Am J Ophthalmol. 2003 Sep;136(3):530-6.
Crossref